The addition of a brief alpha interferon regimen to each CHOP induction cycle, plus one year of alpha interferon thrice weekly maintenance therapy, has no early effect on response rates or survival in patients with Intermediate or High grade cell NHL.
Background: The CHOP (Cyclophosphamide, Adriamycin, Vincristine, Prednisone) regimen is the most widely used first-line therapy for patients with Intermediate or High Grade (IG/HG) non-Hodgkin's lymphoma (NHL). Alpha 2b interferon (INF) enhances response rates and improves survival in low-grade NHL. The International Oncology Study Group (IOSG) conducted a prospective randomized study comparing CHOP alone or combined with INF in patients with IG/HG-NHL. The primary study aim was to compare the objectiveresponse rates in these patient cohorts. Patients and Methods: Patients with a confirmed diagnosis of measurable NHL of International Working Formulation (IWF) groups D to H histology were randomized to receive CHOP alone or CHOP with 5Mu INF SC for 5 days on days 22 to 26 of each 28 day cycle with INF 5 million units (Mu) given three times per week subcutaneously for 52 weeks in those patients who responded to CHOP plus INF Results: The overall response rates were equivalent in both groups: CHOP alone (214 patients) 81% (complete 55%, partial 26%): CHOP plus INF (221 patients) 80% (complete 54%, partial 26%). At 36 months, the actuarial survival rate was equivalent in both groups. Conclusions: There is no apparent early advantage in terms of response or survival conferred by adding the study INF regimen to CHOP therapy for patients with IG/HC-NHL.
C1 Int Oncol Study Grp, Houston, TX USA.
Tata Mem Hosp, Parel, Mombay, India.
Ankara Univ, Ibni Sina Hosp, Sihhiye, Turkey.
Inonu Univ, Turgut Ozal Med Ctr, Malatya, Turkey.
Allama Iqbal Med Coll, Lahore, Pakistan.
Cairo Univ, Sch Med, Cairo, Egypt.
Kidwai Mem Inst Oncol, Bangalore, Karnataka, India.
Univ Ege, Bornova, Turkey.
Chiang Mai Univ, Chiang Mai, Thailand.
Vet Gen Hosp, Taipei, Taiwan.
Univ Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey.
Natl Canc Inst, Cairo, Egypt.
Chulalongkorn Univ, King Chulalongkorn Mem Hosp, Bangkok, Thailand.
Asan Med Ctr, Seoul, South Korea.
Chungam Natl Univ Hosp, Daejoon, South Korea.
All India Inst Med Sci, Inst Rotary Canc Hosp, New Delhi, India.
Ctr Canc, CDR, Hyderabad, Andhra Pradesh, India.
Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
Prince Songkla Univ, Hat Yai, Thailand.
Dharmais Canc Hosp, Jakarta, Indonesia.
Pramongkutklao Coll Med, Bangkok, Thailand.
Shaukat Khanum Mem Canc Hosp, Lahore, Pakistan.
Hillbrow Hosp, Johannesburg, South Africa.
Inst Canc Res, Adyar, Chennai, India.
Alfred Hosp, Melbourne, Vic, Australia.
Kelmyung Univ, Taegu, South Korea.
Kariadi Hosp, Semarang, Indonesia.
Padjadjaran State Univ, Hasan Sadikin Hosp, Bandung, Indonesia.
Singapore Gen Hosp, Singapore 0316, Singapore.
Univ Philippines, Manila, Philippines.
Queen Elizabeth Hosp, Adelaide, SA, Australia.
Natl Univ Singapore Hosp, Singapore 117548, Singapore.
Ankara Gulhane Mil Med Sch, Ankara, Turkey.
Mahidol Univ, Ramathibodi Hosp, Bangkok 10400, Thailand.